TKPYY - Takeda Pharmaceutical Company Limited

Other OTC - Other OTC Delayed Price. Currency in USD
16.59
0.00 (0.00%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close16.59
Open16.62
Bid0.00 x 0
Ask0.00 x 0
Day's Range16.59 - 16.59
52 Week Range15.50 - 31.29
Volume7,820,846
Avg. Volume3,393,495
Market Cap28.177B
Beta (3Y Monthly)0.42
PE Ratio (TTM)20.44
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.79 (4.72%)
Ex-Dividend Date2018-09-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • This pharmaceutical company is like four biotechs in one,...
    CNBC Videosyesterday

    This pharmaceutical company is like four biotechs in one,...

    Takeda Pharmaceutical Company President and CEO Christophe Weber sits down with CNBC's "Squawk on the Street" team after ringing the opening bell.

  • Japan Olympics boss suspected of campaign bribery
    Reuters Videos5 days ago

    Japan Olympics boss suspected of campaign bribery

    The president of Japan's Olympic Committee, Tsunekazu Takeda, has been indicted in France on allegations of corruption, an official has confirmed, related to his country's successful bid to host the 2020 Olympics. Lauren Anthony reports.

  • $59bln: What it costs to become a drugs player
    Reuters Videoslast month

    $59bln: What it costs to become a drugs player

    Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt. Julian Satterthwaite reports.

  • TheStreet.comyesterday

    Takeda Pharmaceutical CEO Talks Big Pharma Trends

    Big pharmaceutical companies have begun 2019 with a bang. $62 billion buyout of Shire Plc have signaled the acquisition appetite in the space is strong. To understand the pipeline still ahead and the rationale for such massive mergers and acquisitions, TheStreet joined Takeda Pharmaceutical's CEO Christophe Weber on the New York Stock Exchange, shortly after his company rang the opening bell to celebrate the Japanese giant's U.S. listing.

  • Reuters5 days ago

    France investigates Japan's Olympics chief on suspicion of corruption

    The president of Japan's Olympic Committee, Tsunekazu Takeda, is under formal investigation in France for suspected corruption related to Japan's successful bid for the 2020 Olympic Games, a French judicial source said on Friday. French financial prosecutors investigating a multi-million dollar payment made by Japan's bidding committee to a Singaporean consultancy questioned Takeda in Paris and he was placed under formal investigation on Dec. 10, the source told Reuters.

  • Financial Times6 days ago

    [$$] Head of Japan Olympic Committee faces French corruption probe

    The president of Japan’s Olympic Committee, Tsunekazu Takeda, has been placed under formal investigation on corruption allegations in France related to Japan’s winning bid to host the 2020 Olympic Games. Mr Takeda, who is helping to put together Japan’s Olympic games next year, was placed under investigation last month on suspicion of “active corruption”, said a spokesperson for the Paris prosecutor’s office.

  • Reuters6 days ago

    Olympics-IOC opens ethics file on Takeda, to meet Friday

    The International Olympic Committee's ethics commission on Friday opened a file on Japan Olympic Committee chief Tsunekazu Takeda after a judicial source in France said he had been indicted by French prosecutors over the successful bid for the 2020 Olympic Games. The IOC Ethics commission has opened a file and will continue to monitor the situation - and is meeting today.

  • Financial Times8 days ago

    [$$] Takeda seeks to divest $10bn of assets after £46bn Shire deal

    Takeda will consider selling businesses from its Nycomed acquisition in 2011, as Japan’s largest pharmaceutical group seeks to divest $10bn of assets after completing a £46bn deal to buy Shire. Christophe ...

  • Takeda's CEO Says It Needs to Sell Assets Quickly to Cut Debt
    Bloomberg8 days ago

    Takeda's CEO Says It Needs to Sell Assets Quickly to Cut Debt

    For one, debt is a huge issue, with net borrowings more than doubling as Takeda takes on about $30 billion in debt to acquire Shire. S&P Global Ratings downgraded Takeda on Tuesday, questioning how quickly it will be able to repair worsening financial ratios. In addition, Weber needs to whip the new Takeda into shape as competition heats up in the pharmaceutical industry.

  • Benzinga9 days ago

    The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...

  • Financial Times9 days ago

    [$$] Takeda completes £46bn acquisition of Shire

    Takeda Pharmaceutical has completed its £46bn acquisition of Shire, catapulting the 237-year-old Japanese group into one of the world’s largest drugmakers with combined revenues of $31bn .   The completion ...

  • How Takeda's $62 Billion Shire Deal Reshapes Pharma World
    Bloomberg9 days ago

    How Takeda's $62 Billion Shire Deal Reshapes Pharma World

    Takeda’s purchase was the world’s biggest announced acquisition of 2018, transforming the 237-year-old Japanese company into a top 10 drugmaker with lucrative therapies for rare diseases and a sizable footprint in the U.S. Already in 2019, the Takeda deal has been trumped in size by Bristol-Myers Squibb Co.’s $74 billion agreement last week to buy Celgene Corp. Takeda and Shire’s combined revenue catapult it into the ranks of the global pharmaceutical majors -- the first Japanese company to reach the top 10.

  • Reuters10 days ago

    Takeda unlikely to sell OTC drug business - CEO

    Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it closes a $59 billion takeover of London-listed Shire, Chief Executive Christophe Weber said on Monday. After the Shire deal, which closes on Tuesday, Takeda will have a stronger pipeline and be counted among the top 10 drugmakers by sales globally. "It's not our first priority," Weber told a news conference when asked whether Takeda would sell its OTC business.

  • Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth
    Market Realist23 days ago

    Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth

    An Overview of Pfizer’s Oncology and Vaccine Business(Continued from Prior Part)Xtandi revenue In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.

  • How Pfizer’s Sutent and Xalkori Have Performed
    Market Realist23 days ago

    How Pfizer’s Sutent and Xalkori Have Performed

    An Overview of Pfizer’s Oncology and Vaccine Business(Continued from Prior Part)Sutent revenue In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.

  • Japan Inc heads abroad in $180bn deal rush
    MarketWatch29 days ago

    Japan Inc heads abroad in $180bn deal rush

    Japanese companies have embarked on the biggest overseas acquisition spree in more than 20 years, echoing the deal boom of the 1980s as they race to buy growth to offset a shrinking domestic market and ageing workforce. Corporate Japan splashed out nearly $180bn on 621 outbound deals so far this year, compared with 685 deals with a total value of almost $80bn for the whole of 2017, according to financial data provider Dealogic. Hitachi (HTHIY)  added another $6.4bn to Japan’s tally of deals on Monday after it bought an 80.1% stake in the power grids division of its Swiss-Swedish rival ABB (ABB) .

  • Moody'slast month

    Takeda Pharmaceutical Company Limited -- Moody's downgrades Takeda to Baa2; outlook stable

    Moody's Japan K.K. has downgraded to Baa2 from A2 the issuer and senior unsecured ratings of Takeda Pharmaceutical Company Limited. At the same time, Moody's has changed the ratings outlook to stable. "This transformative acquisition will cause Takeda's debt to increase almost six-fold, making the company one of the most leveraged pharmaceutical companies rated investment grade," says Moody's analyst Yukiko Asanuma.

  • What Are Tesaro’s Revenue Projections for Fiscal 2018?
    Market Realistlast month

    What Are Tesaro’s Revenue Projections for Fiscal 2018?

    How Is Tesaro Positioned in December? In its third-quarter earnings conference call, Tesaro (TSRO) narrowed its revenue guidance for fiscal 2018 from the previously projected range of $250 million to $265 million to $258 million to $265 million. According to the company’s third-quarter earnings conference call, Tesaro is expected to have cash and cash equivalents worth $400 million on its balance sheet at the end of fiscal 2018.

  • The Wall Street Journallast month

    [$$] Takeda Wins Shareholder Approval for Its Shire Megadeal

    Takeda Pharmaceutical Co. shareholders voted in favor of its megadeal to buy Europe’s Shire PLC on Wednesday, crushing an opposition campaign that sought to derail the biggest overseas acquisition by a Japanese company. At least 88% of votes cast were in favor, according to Takeda, dealing a blow to a group of longtime shareholders who had lobbied to block the cash-and-stock merger, valued at about $58 billion today. The dissidents argued Takeda was overpaying for Shire and piling on too much debt to do so, though they conceded before the vote that they hadn’t won enough support to derail the deal.

  • Reuterslast month

    Takeda clears key hurdle as investors back $59 billion Shire deal

    Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt. Takeda will be joining the ranks of the world's top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company. The company's high debt levels were a top concern for Takeda shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90 percent of them voted to approve the deal as expected.

  • Takeda clears key hurdle as investors back $59 billion Shire deal
    Reuterslast month

    Takeda clears key hurdle as investors back $59 billion Shire deal

    Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire (SHP.L), creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt. Takeda will be joining the ranks of the world's top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company. The company's high debt levels were a top concern for Takeda shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90 percent of them voted to approve the deal as expected.

  • Reuterslast month

    Takeda investors back $59 billion Shire deal, but wary of debt load

    Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion (46.3 billion pounds) takeover of London-listed Shire (SHP.L), creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt. Takeda will be joining the ranks of the world's top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company. The company's high debt levels were a top concern for shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90 percent of them voted to approve the deal as expected.